Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity-Reference-Cited by-同舟云学术

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity

Published:2008-12-30 Issue:2 Volume:52 Page:379-388
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Howard Steven¹,Berdini Valerio¹,Boulstridge John A.¹,Carr Maria G.¹,Cross David M.¹,Curry Jayne¹,Devine Lindsay A.¹,Early Theresa R.¹,Fazal Lynsey¹,Gill Adrian L.¹,Heathcote Michelle¹,Maman Sarita¹,Matthews Julia E.¹,McMenamin Rachel L.¹,Navarro Eva F.¹,O’Brien Michael A.¹,O’Reilly Marc¹,Rees David C.¹,Reule Matthias¹,Tisi Dominic¹,Williams Glyn¹,Vinković Mladen¹,Wyatt Paul G.¹

Affiliation:

1. Astex Therapeutics Ltd., 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm800984v

Reference42 articles.

1. Fragment-Based Drug Discovery

2. Fragment-based lead discovery

3. Fragment-based approaches to enzyme inhibition